Table 1
| ADMIN | STUDY | CLOSE DATE |
Intergroup Study |
OPEN | COOPGRP | COUNT |
|---|---|---|---|---|---|---|
| BREAST | S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab) | Y | ALLIANCE | 125 | ||
| CCTG | 24 | |||||
| ECOG-ACRIN | 117 | |||||
| NRG | 285 | |||||
| SWOG | 519 | |||||
| sum | 1070 | |||||
| S1706-Breast, Inflammatory, RT +/- Olaparib | Y | ALLIANCE | 10 | |||
| CCTG | 1 | |||||
| ECOG-ACRIN | 5 | |||||
| NRG | 24 | |||||
| SWOG | 38 | |||||
| sum | 78 | |||||
| CCD | S1703-Met Breast, STM-monitoring v Usual Care | Y | ALLIANCE | 4 | ||
| ECOG-ACRIN | 15 | |||||
| NRG | 10 | |||||
| SWOG | 113 | |||||
| sum | 142 | |||||
| ERLYTX | S1609-Rare Tumor, Comb Nivo/Ipi | Y | ALLIANCE | 101 | ||
| ECOG-ACRIN | 77 | |||||
| NRG | 131 | |||||
| SWOG | 456 | |||||
| sum | 765 | |||||
| GI | S1613-mCRC, Adv/Met, TP vs CETIRI | Y | ALLIANCE | 5 | ||
| ECOG-ACRIN | 4 | |||||
| NRG | 4 | |||||
| SWOG | 32 | |||||
| sum | 45 | |||||
| S1815-Biliary, Met/LocAdv, GC+CPT±Nab-paclitaxel | 15-FEB-21 | N | ALLIANCE | 122 | ||
| ECOG-ACRIN | 92 | |||||
| NRG | 41 | |||||
| SWOG | 197 | |||||
| sum | 452 | |||||
| S1922-Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect | Y | ALLIANCE | 1 | |||
| NRG | 1 | |||||
| SWOG | 6 | |||||
| sum | 8 | |||||
| S2001-Rando II, Mets Pancreas , BRCA1/2, Comb Chemo | Y | SWOG | 1 | |||
| sum | 1 | |||||
| GU | S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG | 15-DEC-20 | N | ALLIANCE | 110 | |
| ECOG-ACRIN | 111 | |||||
| NRG | 88 | |||||
| SWOG | 691 | |||||
| sum | 1000 | |||||
| S1802-Pros, Stg IV, SST +/- Surg/RT to Primary Tum | Y | ALLIANCE | 56 | |||
| ECOG-ACRIN | 27 | |||||
| NRG | 35 | |||||
| SWOG | 226 | |||||
| sum | 344 | |||||
| S1806-Blad, MIBC, ChemoRT +/- Atezolizumab | Y | ALLIANCE | 5 | |||
| ECOG-ACRIN | 14 | |||||
| NRG | 33 | |||||
| SWOG | 88 | |||||
| sum | 140 | |||||
| S1931-RENAL, Stg IV, IO + Nephrectomy. vs IO Only | Y | SWOG | 1 | |||
| sum | 1 | |||||
| LEUK | S1318-ALL, Age 65+, Ph±, Blinatumomab | 15-APR-21 | T | ALLIANCE | 17 | |
| ECOG-ACRIN | 6 | |||||
| NRG | 2 | |||||
| SWOG | 32 | |||||
| sum | 57 | |||||
| S1712-CML, Chronic Phase, TKI +/- Ruxolitinib | Y | ALLIANCE | 7 | |||
| ECOG-ACRIN | 4 | |||||
| NRG | 2 | |||||
| SWOG | 39 | |||||
| sum | 52 | |||||
| S1905-T-ALL/T-LBL, Rel/Ref, OBI-3424 | Y | SWOG | 1 | |||
| sum | 1 | |||||
| S1925-CLL/SLL, Newly Dx HR, Early vs Delayed V+O | Y | SWOG | 2 | |||
| sum | 2 | |||||
| LUNG | LUNGMAP-NSCLC, Adv, Master | Y | ALLIANCE | 470 | ||
| ECOG-ACRIN | 237 | |||||
| NRG | 213 | |||||
| SWOG | 1005 | |||||
| sum | 1925 | |||||
| S1701-Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac | Y | ALLIANCE | 2 | |||
| ECOG-ACRIN | 1 | |||||
| SWOG | 8 | |||||
| sum | 11 | |||||
| S1800A-Non-Match: Ramu + Pembro vs SoC | 16-NOV-20 | N | ALLIANCE | 36 | ||
| ECOG-ACRIN | 17 | |||||
| NRG | 15 | |||||
| SWOG | 98 | |||||
| sum | 166 | |||||
| S1827-SCLC, MRI Surveillance +/- PCI | Y | ALLIANCE | 8 | |||
| ECOG-ACRIN | 1 | |||||
| NRG | 12 | |||||
| SWOG | 12 | |||||
| sum | 33 | |||||
| S1900B-RET Fusion: Selpercatinib (LOXO-292) | Y | ALLIANCE | 1 | |||
| ECOG-ACRIN | 2 | |||||
| NRG | 2 | |||||
| SWOG | 1 | |||||
| sum | 6 | |||||
| S1900C-STK11: Talazoparib + Avelumab | 16-NOV-20 | N | ALLIANCE | 9 | ||
| ECOG-ACRIN | 7 | |||||
| NRG | 2 | |||||
| SWOG | 29 | |||||
| sum | 47 | |||||
| S1914-NSCLC, High Risk Early Stg, SBRT +/- Atezo | Y | ECOG-ACRIN | 2 | |||
| SWOG | 17 | |||||
| sum | 19 | |||||
| S1929-ESCLC, SLFN11+, Atezolizumab ± Talazoparib | Y | ALLIANCE | 1 | |||
| NRG | 3 | |||||
| SWOG | 16 | |||||
| sum | 20 | |||||
| S1933-NSCLC, Stg II-III, RT + Atezo | Y | SWOG | 2 | |||
| sum | 2 | |||||
| LYMPH | S1608-FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob | Y | ALLIANCE | 10 | ||
| ECOG-ACRIN | 4 | |||||
| NRG | 11 | |||||
| SWOG | 35 | |||||
| sum | 60 | |||||
| S1826-HD, Adv, Age 12+, N+AVD vs BV+AVD | Y | ALLIANCE | 53 | |||
| COG | 138 | |||||
| ECOG-ACRIN | 34 | |||||
| NRG | 23 | |||||
| SWOG | 157 | |||||
| sum | 405 | |||||
| MELAN | S1512-Melan, Adv, Desmoplastic, MK-3475 (pembro) | Y | ECOG-ACRIN | 1 | ||
| SWOG | 45 | |||||
| S1512 | Y | ALLIANCE | 1 | |||
| NRG | 4 | |||||
| sum | 51 | |||||
| S1801-Melan, Adv, Adj vs Neoadj Pembrolizumab | Y | ALLIANCE | 17 | |||
| ECOG-ACRIN | 33 | |||||
| NRG | 33 | |||||
| SWOG | 138 | |||||
| sum | 221 | |||||
| S2000-MELAN, M1d/ BRAF, Enco+Bini+Nivo vs Ipil+Nivo | Y | NRG | 1 | |||
| SWOG | 3 | |||||
| sum | 4 | |||||
| MMYEL | S1803-MM, Maintenance, Len vs Len/Dara | Y | ALLIANCE | 73 | ||
| ECOG-ACRIN | 55 | |||||
| NRG | 34 | |||||
| SWOG | 226 | |||||
| sum | 388 | |||||
| PEOLC | S1820-Rectal, Diet modification to manage GI sx | Y | ALLIANCE | 3 | ||
| ECOG-ACRIN | 1 | |||||
| NRG | 15 | |||||
| SWOG | 31 | |||||
| sum | 50 | |||||
| PREV | S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac | Y | ALLIANCE | 32 | ||
| ECOG-ACRIN | 26 | |||||
| NRG | 35 | |||||
| SWOG | 220 | |||||
| sum | 313 | |||||
| S1823-GCT, Obs. Cohort, miRNA371 | Y | ALLIANCE | 14 | |||
| CCTG | 16 | |||||
| ECOG-ACRIN | 14 | |||||
| NRG | 4 | |||||
| SWOG | 84 | |||||
| sum | 132 | |||||
| S1904-Breast, Decision making for chemoprevention | Y | ALLIANCE | 2 | |||
| SWOG | 21 | |||||
| sum | 23 | |||||
| SURV | S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol | Y | ECOG-ACRIN | 31 | ||
| SWOG | 168 | |||||
| S1501 | Y | ALLIANCE | 18 | |||
| NRG | 18 | |||||
| sum | 235 | |||||
| SXQOL | S1600-Bladder,Radical Cystectomy Outcomes Nutrition | Y | ALLIANCE | 2 | ||
| NRG | 1 | |||||
| SWOG | 55 | |||||
| sum | 58 | |||||